6 active not recruiting, 5 recruiting, 2 completed, 2 terminated. 17 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Active not recruiting 6, Recruiting 5, Completed 2, Terminated 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Locally Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Locally Advanced Malignant Solid Neoplasm trials Research Report on Locally Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2023-09-22 | 2026-08-24 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-11-12 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors Larotrectinib Sulfate - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 13 | 2021-04-30 | 2026-10-07 |
| CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001 - Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Terminated | University of Southern California | 2 | 2021-04-29 | 2026-04-17 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-04-26 | 2026-11-12 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor Pembrolizumab, Pevonedistat - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2021-03-29 | 2022-12-27 |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Avapritinib - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2021-01-20 | 2026-06-11 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-11-12 |
| Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers Pembrolizumab - Locally Advanced Malignant Solid Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 35 | 2019-10-31 | 2025-05-13 |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 115 | 2019-07-16 | 2026-11-12 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression | Phase 2 | Withdrawn | Sameek Roychowdhury | 2019-03-20 | 2022-02-18 | |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Adavosertib - Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-01-29 | 2026-10-23 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Ceralasertib, Olaparib, Durvalumab - Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer | Phase 2 | Active not recruiting | Rahul Aggarwal | 83 | 2019-01-17 | 2026-04-23 |
| Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer Dexamethasone, Exercise Intervention, Placebo Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 99 | 2018-06-29 | 2026-07-09 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Biopsy, Biospecimen Collection, Computed Tomography - Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2013-10-08 | 2025-01-14 |
Neoplasm Metastasis (15) · Endometrial Neoplasms (4) · Pancreatic Neoplasms (4) · Carcinoma, Renal Cell (3) · Carcinoma, Transitional Cell (3) · Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1)
Neoplasms (15) · Neoplastic Processes (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Neoplasms by Site (11) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Neoplasms by Histologic Type (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Carcinoma (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5)
Biopsy (7) · Specimen Handling (7) · Magnetic Resonance Spectroscopy (5) · Paclitaxel (3) · Taxes (3) · pembrolizumab (3) · Immunoglobulin G (2) · durvalumab (2) · ipatasertib (2) · olaparib (2) · 130-nm albumin-bound paclitaxel (1) · ADP Ribose Transferases (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · CYT003-QbG10 (1)
National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · Haihua Yuan (1) · Mayo Clinic (1) · Rahul Aggarwal (1) · Sameek Roychowdhury (1) · University of Southern California (1)
United States (16) · Puerto Rico (2)
A P Chen (2) · Antoni Ribas (1) · David S Hong (1) · Diana L Hanna, MD (1) · James M Ford (1) · Jordi Rodon Ahnert (1) · Kristen R Spencer (1) · Michael J Overman (1) · Michael J Overman, MD (1) · Rahul Aggarwal, MD (1) · Rahul R Aggarwal (1) · Reva K Basho (1) · Sameek Roychowdhury, MD (1) · Sriram Yennu (1) · Yanyan Lou, MD, PhD (1)
PMID 33416261, PMID 36623241, PMID 38261444, PMID 38920407, PMID 39773433, PMID 41686845
U10CA180888 (2), P30CA014089 (1), P30CA016058 (1), R21NR016737 (1), U10CA032102 (1), U10CA180820 (1), U10CA180830 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186716 (1), ZIABC011078 (1)